全文获取类型
收费全文 | 433篇 |
免费 | 37篇 |
国内免费 | 1篇 |
出版年
2022年 | 6篇 |
2021年 | 19篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 11篇 |
2017年 | 10篇 |
2016年 | 8篇 |
2015年 | 15篇 |
2014年 | 17篇 |
2013年 | 24篇 |
2012年 | 28篇 |
2011年 | 37篇 |
2010年 | 12篇 |
2009年 | 12篇 |
2008年 | 17篇 |
2007年 | 16篇 |
2006年 | 22篇 |
2005年 | 24篇 |
2004年 | 14篇 |
2003年 | 23篇 |
2002年 | 10篇 |
1999年 | 3篇 |
1998年 | 6篇 |
1996年 | 6篇 |
1994年 | 3篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1986年 | 3篇 |
1984年 | 6篇 |
1982年 | 3篇 |
1981年 | 3篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 4篇 |
1975年 | 4篇 |
1967年 | 4篇 |
1963年 | 2篇 |
1961年 | 3篇 |
1960年 | 2篇 |
1956年 | 2篇 |
1950年 | 2篇 |
1948年 | 2篇 |
1941年 | 3篇 |
1932年 | 2篇 |
1931年 | 3篇 |
1930年 | 2篇 |
1929年 | 2篇 |
1927年 | 3篇 |
排序方式: 共有471条查询结果,搜索用时 62 毫秒
71.
72.
73.
74.
75.
VLJ Whitehall TD Dumenil DM McKeone CE Bond ML Bettington RL Buttenshaw L Bowdler GW Montgomery LF Wockner BA Leggett 《Epigenetics》2014,9(11):1454-1460
The CpG Island Methylator Phenotype (CIMP) is fundamental to an important subset of colorectal cancer; however, its cause is unknown. CIMP is associated with microsatellite instability but is also found in BRAF mutant microsatellite stable cancers that are associated with poor prognosis. The isocitrate dehydrogenase 1 (IDH1) gene causes CIMP in glioma due to an activating mutation that produces the 2-hydroxyglutarate oncometabolite. We therefore examined IDH1 alteration as a potential cause of CIMP in colorectal cancer. The IDH1 mutational hotspot was screened in 86 CIMP-positive and 80 CIMP-negative cancers. The entire coding sequence was examined in 81 CIMP-positive colorectal cancers. Forty-seven cancers varying by CIMP-status and IDH1 mutation status were examined using Illumina 450K DNA methylation microarrays. The R132C IDH1 mutation was detected in 4/166 cancers. All IDH1 mutations were in CIMP cancers that were BRAF mutant and microsatellite stable (4/45, 8.9%). Unsupervised hierarchical cluster analysis identified an IDH1 mutation-like methylation signature in approximately half of the CIMP-positive cancers. IDH1 mutation appears to cause CIMP in a small proportion of BRAF mutant, microsatellite stable colorectal cancers. This study provides a precedent that a single gene mutation may cause CIMP in colorectal cancer, and that this will be associated with a specific epigenetic signature and clinicopathological features. 相似文献
76.
Sapna Oberoi Gabriele Zamperlini–Netto Joseph Beyene Nathaniel S. Treister Lillian Sung 《PloS one》2014,9(9)
Background
Objective was to determine whether prophylactic low level laser therapy (LLLT) reduces the risk of severe mucositis as compared to placebo or no therapy.Methods
MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched until February 2014 for randomized controlled trials (RCTs) comparing prophylactic LLLT with placebo or no therapy in patients with cancer or undergoing hematopoietic stem cell transplantation (HSCT). All analyses used random effects models.Results
Eighteen RCTs (1144 patients) were included. Prophylactic LLLT reduced the overall risk of severe mucositis (risk ratio (RR) 0.37, 95% confidence interval (CI) 0.20 to 0.67; P = 0.001). LLLT also reduced the following outcomes when compared to placebo/no therapy: severe mucositis at the time of anticipated maximal mucositis (RR 0.34, 95% CI 0.20 to 0.59), overall mean grade of mucositis (standardized mean difference −1.49, 95% CI −2.02 to −0.95), duration of severe mucositis (weighted mean difference −5.32, 95% CI −9.45 to −1.19) and incidence of severe pain (RR 0.26, 95% CI 0.18 to 0.37).Conclusion
Prophylactic LLLT reduced severe mucositis and pain in patients with cancer and HSCT recipients. Future research should identify the optimal characteristics of LLLT and determine feasibility in the clinical setting. 相似文献77.
Lillian Louren?o Guillaume Colley Bohdan Nosyk Dmitry Shopin Julio S. G. Montaner Viviane D. Lima 《PloS one》2014,9(12)
Background
The HIV cascade of care (cascade) is a comprehensive tool which identifies attrition along the HIV care continuum. We executed analyses to explicate heterogeneity in the cascade across key strata, as well as identify predictors of attrition across stages of the cascade.Methods
Using linked individual-level data for the population of HIV-positive individuals in BC, we considered the 2011 calendar year, including individuals diagnosed at least 6 months prior, and excluding individuals that died or were lost to follow-up before January 1st, 2011. We defined five stages in the cascade framework: HIV ‘diagnosed’, ‘linked’ to care, ‘retained’ in care, ‘on HAART’ and virologically ‘suppressed’. We stratified the cascade by sex, age, risk category, and regional health authority. Finally, multiple logistic regression models were built to predict attrition across each stage of the cascade, adjusting for stratification variables.Results
We identified 7621 HIV diagnosed individuals during the study period; 80% were male and 5% were <30, 17% 30–39, 37% 40–49 and 40% were ≥50 years. Of these, 32% were MSM, 28% IDU, 8% MSM/IDU, 12% heterosexual, and 20% other. Overall, 85% of individuals ‘on HAART’ were ‘suppressed’; however, this proportion ranged from 60%–93% in our various stratifications. Most individuals, in all subgroups, were lost between the stages: ‘linked’ to ‘retained’ and ‘on HAART’ to ‘suppressed’. Subgroups with the highest attrition between these stages included females and individuals <30 years (regardless of transmission risk group). IDUs experienced the greatest attrition of all subgroups. Logistic regression results found extensive statistically significant heterogeneity in attrition across the cascade between subgroups and regional health authorities.Conclusions
We found that extensive heterogeneity in attrition existed across subgroups and regional health authorities along the HIV cascade of care in B.C., Canada. Our results provide critical information to optimize engagement in care and health service delivery. 相似文献78.
79.
Sandra Blanco Sabine Dietmann Joana V Flores Shobbir Hussain Claudia Kutter Peter Humphreys Margus Lukk Patrick Lombard Lucas Treps Martyna Popis Stefanie Kellner Sabine M Hölter Lillian Garrett Wolfgang Wurst Lore Becker Thomas Klopstock Helmut Fuchs Valerie Gailus‐Durner Martin Hrabĕ de Angelis Ragnhildur T Káradóttir Mark Helm Jernej Ule Joseph G Gleeson Duncan T Odom Michaela Frye 《The EMBO journal》2014,33(18):2020-2039
80.
Natália Martins Isabel C. F. R. Ferreira Lillian Barros Sónia Silva Mariana Henriques 《Mycopathologia》2014,177(5-6):223-240
Candidiasis is the most common opportunistic yeast infection. Candida species and other microorganisms are involved in this complicated fungal infection, but Candida albicans continues to be the most prevalent. In the past two decades, it has been observed an abnormal overgrowth in the gastrointestinal, urinary and respiratory tracts, not only in immunocompromised patients, but also related to nosocomial infections and even in healthy individuals. There is a widely variety of causal factors that contribute to yeast infection which means that candidiasis is a good example of a multifactorial syndrome. Due to rapid increase in the incidence in these infections, this is the subject of numerous studies. Recently, the focus of attention is the treatment and, above all, the prevention of those complications. The diagnosis of candidiasis could become quite complicated. Prevention is the most effective “treatment,” much more than eradication of the yeast with antifungal agents. There are several aspects to consider in the daily routine that can provide a strength protection. However, a therapeutic approach is necessary when the infection is established, and therefore, other alternatives should be explored. This review provides an overview on predisposition factors, prevention and diagnosis of candidiasis, highlighting alternative approaches for candidiasis treatment. 相似文献